



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office : Energy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED ON 30TH JUNE, 2019

(Rs. in lakhs)

SI.No.	PART I - Particulars	Quarter ended			Year ended
		30-06-2019	31-03-2019	30-06-2018	31-03-2019
		Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	41,080.05	37,914.77	36,590.68	1,50,118.70
2	Other Income	1,233.75	1,528.85	118.21	4,022.50
3	Total Income (1+2)	42,313.80	39,443.62	36,708.89	1,54,141.20
4	Expenses				
	a. Cost of materials consumed	12,617.74	11,774.30	11,100.08	45,375.37
	b. Purchases of stock-in-trade	1,365.41	2,702.54	2,469.39	10,426.13
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,006.43	98.18	(409.59)	(2,165.74)
	d. Employee benefit expenses	7,064.11	6,758.24	5,937.70	25,797.86
	e. Finance Costs	80.37	85.78	127.23	411.51
	f. Depreciation and amortization expense	1,562.91	1,140.81	1,446.52	5,482.49
	g. Other Expenses	9,800.88	10,634.35	10,089.44	41,886.05
	Total Expenses (4)	33,497.85	33,194.20	30,760.77	1,27,213.67
5	Profit before Tax (3-4)	8,815.95	6,249.42	5,948.12	26,927.53
6	Tax expenses	2,901.31	2,031.91	1,741.07	8,721.61
7	Net Profit after Tax for the period (5-6)	5,914.64	4,217.51	4,207.05	18,205.92
8	Other Comprehensive Income (net of Tax)	(5.20)	214.66	(61.80)	29.25
9	Total Comprehensive Income after Tax (7+8)	5,909.44	4,432.17	4,145.25	18,235.17
10	Earning per share (EPS) (of Rs. 2/- each not annualised)				
	(1) Basic	7.37	5.13	5.03	22.15
	(2) Diluted	7.37	5.13	5.03	22.15

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on August 13, 2019.
- The auditors have carried out limited review of the financial results for the quarter ended on June 30, 2019 and their report does not contain any qualification.
- Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Company has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the statement of profit and loss for the current period, Compensation Rent expenses has changed to depreciation cost for the right of use asset and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter ended June 30, 2019 is not material. To this extent, performance for the current period ended June 30, 2019 is not comparable with previous period results.
- The Company has one reportable segment viz. Pharmaceuticals.
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the third quarter of the financial year 2018-19.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B.Mody
Chairman & Managing Director

Place : Mumbai
Date : 13/08/2019



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.

Corporate Office : Energy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.

Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334

CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED ON 30TH JUNE, 2019

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended
		30-06-2019	31-03-2019	30-06-2018	31-03-2019
		Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	44,611.03	41,891.55	40,691.61	1,64,320.04
2	Other Income	1,260.80	1,565.09	141.61	4,143.99
3	Total Income (1+2)	45,871.83	43,456.64	40,833.22	1,68,464.03
4	Expenses				
	a. Cost of materials consumed	12,617.74	11,774.30	11,100.08	45,375.37
	b. Purchases of stock-in-trade	3,096.97	3,829.46	4,505.87	16,209.91
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	960.15	793.30	(947.25)	(1,939.38)
	d. Employee benefit expenses	7,805.41	7,470.22	6,746.40	28,817.59
	e. Finance Costs	80.37	78.42	127.89	419.81
	f. Depreciation and amortization expense	1,579.79	1,160.03	1,468.96	5,564.20
	g. Other Expenses	10,532.85	11,522.61	11,204.32	45,317.27
	Total Expenses (4)	36,673.28	36,628.34	34,206.27	1,39,764.77
5	Profit before Tax (3-4)	9,198.55	6,828.30	6,626.95	28,699.26
6	Tax expenses	2,987.42	2,149.27	2,051.27	9,302.29
7	Net Profit after Tax for the period (5-6)	6,211.13	4,679.03	4,575.68	19,396.97
8	Other Comprehensive Income (net of Tax)	191.64	276.20	(271.11)	(419.64)
9	Total Comprehensive Income after Tax (7+8)	6,402.77	4,955.23	4,304.57	18,977.33
10	Net Profit after Tax for the period attributable to:				
	- owners of the company	6,200.65	4,665.71	4,562.55	19,346.63
	- non controlling interest	10.48	13.32	13.13	50.34
11	Other comprehensive income for the period attributable to :				
	- owners of the company	182.55	277.67	(239.19)	(372.44)
	- non controlling interest	9.09	(1.47)	(31.92)	(47.20)
12	Total Comprehensive Income after Tax attributable to:				
	- owners of the company	6,383.20	4,943.38	4,323.36	18,974.19
	- non controlling interest	19.57	11.85	(18.79)	3.14
13	Earning per share(EPS) (of Rs. 2/- each not annualised)				
	(1) Basic	7.73	5.68	5.46	23.54
	(2) Diluted	7.73	5.68	5.46	23.54

NOTES

- The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on August 13, 2019.
- The auditors have carried out limited review of the consolidated financial results for the quarter ended on June 30, 2019 and their report does not contain any qualification.
- The consolidated financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements.
- Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Group has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the statement of profit and loss for the current period, Compensation Rent expenses has changed to depreciation cost for the right of use asset and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter ended June 30, 2019 is not material. To this extent, performance for the current period ended June 30, 2019 is not comparable with previous period results.

- 5 The Group has one reportable segment viz. Pharmaceuticals.
- 6 The consolidated figures of the quarter ended March 31, 2019 are balancing figures between audited figures in respect of full financial year ended on March 31, 2019 and the unaudited year to date figures up to December 31, 2018. The consolidated figures for the corresponding quarter ended June 30, 2018, year to date figures up to December 31, 2018 and for the quarter ended March 31, 2019 are approved by the Board of Directors and have not been subjected to Limited review by the auditors.
- 7 The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.



J.B.Mody
Chairman & Managing Director

Place : Mumbai
Date : 13/08/2019